Vinge has advised EQT Infrastructure II in connection with entering into an agreement to divest the Hector Rail group to Ancala’s European Infrastructure Fund II.
The board of directors of Medicover has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby Medicover will raise proceeds of SEK 1.5 billion, before issue costs.
Vinge has advised VNV Global in connection with the process of changing the group’s domicile from Bermuda to Sweden (the “Redomestication”). The Redomestication is carried out by way of a scheme of arrangement under Bermuda law, whereby Swedish Depository Receipts in VNV Global Ltd. will be exchanged for shares in the Swedish group entity VNV Global AB (publ) that, following the Redomestication, will constitute the new parent company of the group. The shares of VNV Global AB (publ) will be listed on the main market of Nasdaq Stockholm.
Vinge has advised Nanoform Finland Plc (“Nanoform”) in connection with its capital raising and listing on Nasdaq First North Premier Growth markets Finland and Sweden.
Vinge has advised worldwide leader in vehicle safety systems, Autoliv, Inc., and its subsidiaries in connection with the entering into of a new SEK 6,000,000,000 loan facility, divided in SEK 3,000,000,000 as a 2-year trance and SEK 3,000,000,000 as a 5-year trance, with SEK, supported by guarantees from EKN.
Vinge has advised the hosting company GleSYS in conjunction with the acquisition of Oulun DataCenter, which is the largest cloud base supplier in northern Finland. The acquisition is part of GleSYS’ strategic growth in the Nordic Region.
Vinge has advised the fintech company Anyfin AB in connection with an investment round of approximately MSEK 300, in which EQT Ventures as a new investor, as well as a number existing investors such as Accel, Northzone, Global Founders Capital and Fintech Collective, are participating.
The global technology company Altair has acquired the WRAP software business from Wrap International AB. The acquisition is a strategic complement to Altair’s portfolio.
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 1,414 million, before issue costs.
